MoonLake Immunotherapeutics
MLTX$1.14B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaZUG100 employees
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Jan 15, 2027
41wMarket Overview
Stock performance and key metrics
MLTX News
Catalyst Timeline
3 upcoming, 1 past
Drug Pipeline
Sonelokimab
Hidradenitis Suppurativa
Risankizumab
Arthritis, Psoriatic
Adalimumab
Arthritis, Psoriatic
Sonelokimab (M1095)
Hidradenitis Suppurativa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sonelokimab | Phase 3 | Hidradenitis Suppurativa | - | - |
Risankizumab | Phase 3 | Arthritis, Psoriatic | - | - |
Adalimumab | Phase 2 | Arthritis, Psoriatic | - | - |
Sonelokimab (M1095) | Phase 2 | Hidradenitis Suppurativa | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply